HBM's Obesity Drug Receives IND Application Acceptance by China's NMPA

MT Newswires Live11-19 13:43

China's National Medical Products Administration (NMPA) accepted HBM Holdings' (HKG:2142) investigational new drug (IND) application for LET003, its AI-developed monoclonal antibody candidate targeting ACVR2A/ACVR2B for overweight and obesity treatment, according to a Thursday Hong Kong bourse filing.

In preclinical studies, LET003 combined with semaglutide enhanced fat reduction while preserving lean mass, the company said. It also showed lean-mass-promoting effects at a lower dose comparable with those of bimagrumab at a higher dose.

Shares of HBM Holdings fell more than 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment